Literature DB >> 30711068

Perceptions of Response Burden Associated with Completion of Patient-Reported Outcome Assessments in Oncology.

Thomas M Atkinson1, Carolyn E Schwartz2, Leah Goldstein3, Iliana Garcia4, Daniel F Storfer3, Yuelin Li3, Jie Zhang5, Bernard H Bochner3, Bruce D Rapkin4.   

Abstract

BACKGROUND: Patient response burden is often raised as a human subject concern in consideration of the length or complexity of patient-reported outcome (PRO) instruments used in oncology.
OBJECTIVES: To quantify patient response burden and identify its predictive factors.
METHODS: Data were collected presurgically during a prospective trial that used a comprehensive symptom and health-related quality-of-life (HRQOL) PRO assessment. A subset of patients also completed HRQOL interviews. Response burden was captured using an internally developed six-item instrument. Demographic and clinical characteristics as well as HRQOL scores were examined as potential predictors using hierarchical regression. Response burden was used to predict participant dropout at the first follow-up interval.
RESULTS: A total of 275 patients (mean age 67.5 years; 23.6% female) completed surveys (n = 126) or surveys in addition to interviews (n = 149). Patients experienced low response burden (mean 12.19 ± 11.65). Repetitive questions were identified by 60 patients (21.8%), whereas 31.6% indicated that additional information should be gathered; 35 patients (12.7%) identified repetitive questions and expressed a desire for additional items. Low self-reported cognitive function was a significant predictor of higher response burden (β = -0.20; t(270) = -3.38; P = 0.01; model-adjusted R2 = 0.04). Response burden was not a significant predictor of study dropout.
CONCLUSIONS: Despite completing a large battery of PRO measures and interviews, patients reported minimal response burden, with nearly one-third expressing that more questions should have been asked. Patients with lower cognitive function are more likely to report higher response burden when completing PRO measures. Further examination of patient characteristics related to response burden may reveal useful pathways for tailoring patient-centered interventions.
Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clinical outcome assessments; neoplasms; patient-centered outcomes; patient-reported outcomes; response burden

Mesh:

Year:  2018        PMID: 30711068      PMCID: PMC6362460          DOI: 10.1016/j.jval.2018.07.875

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  38 in total

1.  The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life.

Authors:  M A Sprangers; A te Velde; N K Aaronson
Journal:  Eur J Cancer       Date:  1999-02       Impact factor: 9.162

Review 2.  Response burden and questionnaire length: is shorter better? A review and meta-analysis.

Authors:  Sindre Rolstad; John Adler; Anna Rydén
Journal:  Value Health       Date:  2011-08-02       Impact factor: 5.725

3.  The Satisfaction With Life Scale.

Authors:  E Diener; R A Emmons; R J Larsen; S Griffin
Journal:  J Pers Assess       Date:  1985-02

4.  PCORI at 3 years--progress, lessons, and plans.

Authors:  Joseph V Selby; Steven H Lipstein
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

5.  Mastectomy patients and the fear of cancer recurrence.

Authors:  L L Northouse
Journal:  Cancer Nurs       Date:  1981-06       Impact factor: 2.592

6.  The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer.

Authors:  Larissa K Temple; Jennifer Bacik; Salvatore G Savatta; Lester Gottesman; Philip B Paty; Martin R Weiser; José G Guillem; Bruce D Minsky; Michelle Kalman; Howard T Thaler; Deborah Schrag; W Douglas Wong
Journal:  Dis Colon Rectum       Date:  2005-07       Impact factor: 4.585

7.  Idiographic quality of life assessment before radical cystectomy.

Authors:  Christopher B Anderson; Bruce Rapkin; Brieyona C Reaves; Arony J Sun; Bradley Morganstern; Guido Dalbagni; Machele Donat; Harry W Herr; Vincent P Laudone; Bernard H Bochner
Journal:  Psychooncology       Date:  2015-11-30       Impact factor: 3.894

8.  Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group.

Authors:  J S Uebersax; J F Wyman; S A Shumaker; D K McClish; J A Fantl
Journal:  Neurourol Urodyn       Date:  1995       Impact factor: 2.696

Review 9.  New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment.

Authors:  Ethan Basch
Journal:  Annu Rev Med       Date:  2013-11-20       Impact factor: 13.739

10.  Reconsidering the psychometrics of quality of life assessment in light of response shift and appraisal.

Authors:  Carolyn E Schwartz; Bruce D Rapkin
Journal:  Health Qual Life Outcomes       Date:  2004-03-23       Impact factor: 3.186

View more
  9 in total

Review 1.  Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort.

Authors:  Matthew B Clements; Thomas M Atkinson; Guido M Dalbagni; Yuelin Li; Andrew J Vickers; Harry W Herr; S Machele Donat; Jaspreet S Sandhu; Daniel S Sjoberg; Amy L Tin; Bruce D Rapkin; Bernard H Bochner
Journal:  Eur Urol       Date:  2021-10-08       Impact factor: 20.096

Review 2.  Assessing Pain Research: A Narrative Review of Emerging Pain Methods, Their Technosocial Implications, and Opportunities for Multidisciplinary Approaches.

Authors:  Sara E Berger; Alexis T Baria
Journal:  Front Pain Res (Lausanne)       Date:  2022-06-02

3.  A narrative review of current evidence supporting the implementation of electronic patient-reported outcome measures in the management of chronic diseases.

Authors:  Olalekan Lee Aiyegbusi; Devika Nair; John Devin Peipert; Kara Schick-Makaroff; Istvan Mucsi
Journal:  Ther Adv Chronic Dis       Date:  2021-05-24       Impact factor: 5.091

4.  A feasibility study of implementing a patient-centered outcome set for pregnancy and childbirth.

Authors:  Anne L Depla; Hiske E Ernst-Smelt; Marjolein Poels; Neeltje M Crombag; Arie Franx; Mireille N Bekker
Journal:  Health Sci Rep       Date:  2020-06-26

5.  Implementation of a standard outcome set in perinatal care: a qualitative analysis of barriers and facilitators from all stakeholder perspectives.

Authors:  Anne L Depla; Neeltje M Crombag; Arie Franx; Mireille N Bekker
Journal:  BMC Health Serv Res       Date:  2021-02-02       Impact factor: 2.655

6.  Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating Factor (SEQ-G-CSF).

Authors:  Aylin Yucel; Anne Skalicky; Olabimpe Ruth Eseyin; Emre Yucel; Rajesh Belani; Mark Bensink
Journal:  J Patient Rep Outcomes       Date:  2021-01-18

Review 7.  Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection.

Authors:  Olalekan Lee Aiyegbusi; Jessica Roydhouse; Samantha Cruz Rivera; Paul Kamudoni; Peter Schache; Roger Wilson; Richard Stephens; Melanie Calvert
Journal:  Nat Commun       Date:  2022-10-12       Impact factor: 17.694

8.  Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.

Authors:  Zachary W Veitch; Daniel Shepshelovich; Christina Gallagher; Lisa Wang; Albiruni R Abdul Razak; Anna Spreafico; Philippe L Bedard; Lillian L Siu; Lori Minasian; Aaron R Hansen
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506

Review 9.  Respondent Understanding in Discrete Choice Experiments: A Scoping Review.

Authors:  Alison Pearce; Mark Harrison; Verity Watson; Deborah J Street; Kirsten Howard; Nick Bansback; Stirling Bryan
Journal:  Patient       Date:  2020-11-03       Impact factor: 3.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.